Founded in 1999, Sparks-based TrimGen Corporation develops genetic testing products and proprietary molecular technologies for clinical research and early disease detection. Its work includes the patented Shifted Termination Assay for sensitive mutation analysis and WaxFree extraction technology, which is designed to recover nucleic acids from limited FFPE and FNA tissue. TrimGen says its products are used by clinical laboratories globally and have been cited in hundreds of academic publications.
FDA 510(k) quality assured reagents
compliance_program